NANEXA.ST
Nanexa AB (publ) [NANEXA.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NANEXA.ST Stock Summary
Top 10 Correlated Stocks
NANEXA.ST
In the News
NANEXA.ST Financial details
Company Rating
-
Market Cap
108.29M
Income
-76.4M
Revenue
29.33M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
19
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-1.85
Forward P/E
-
PEG
0.93
P/S
3.42
P/B
0.95
P/C
-
P/FCF
-2.03
Quick Ratio
0.55
Current Ratio
0.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.93
EPS next Y
-
EPS next Q
-
EPS this Y
-6.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.12%
Revenue last 5Y
76.54%
Revenue Q/Q
1.99%
EPS Q/Q
372.73%
-
-
-
-
SMA20
-
SMA50
100%
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-35%
ROE
-45%
ROC
-0.49%
Gross Margin
92%
Oper. Margin
-185%
Profit Margin
-185%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.65-4.25
52W High
-
52W Low
-
RSI
56
Rel Volume
1.59
Avg Volume
411.8K
Volume
654.85K
Perf Week
9.81%
Perf Month
8.25%
Perf Quarter
8.25%
Perf Half Y
1.55%
-
-
-
-
Beta
1.382
-
-
Volatility
0.12%, 0.21%
Prev Close
-0.65%
Price
2.295
Change
-9.65%
Company Profile
- Volume Average 411.8K
- Market Capitalization 108.29M
- Employee 19
- CEO Mr. David Westberg
- Headquarters Uppsala,SE
- IPO Date 2015-06-17
-
Website
https://www.nanexa.com 
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
